

Supplementary Information

Manuscript title: The human blood parasite *Schistosoma mansoni* expresses extracellular tegumental calpains that cleave the blood clotting protein fibronectin.

Author list: Qiang Wang, Akram A. Da'dara, Patrick J. Skelly

SmCalp1	MG-RIQIVYSPD-----ENVSGRTNRPGKEVV-DPRTGRIIKVKRETPDDYLNVLKPIKG	53
SmCalp2	MQSNPTSNYSMENKLENLNICGNAFGYGHNSSSQYKLRDKTGYPPDTPQKYVNDMRTARH	60
SmCalp1	P-KRMEFNPYL---PKTLTPKGYAKF-----KLMMNVASKQYETLVKRLKTER	97
SmCalp2	NTRAMLFDPERSPLSSKVTENNYCRASPSVVRNPSTVFSVGGPSSSFEKIRQDLLNSG	120
SmCalp1	TLWEDPDFPANDKAIGNLPDFRERIIEWKRPHEINPNA-----KFFAGG	140
SmCalp2	HLFCDSAFPADDSSLYYSQRPPCQIVWMPRSEIIVAANSGGGSMGITPRKISTPEFIGEGG	180
SmCalp1	ASRFDIEQGALGDCWLLAVVASISGYPQLFDQVVPKDQELKGPEYVGVVRFWFWRFGHWV	200
SmCalp2	IKLGELELQGELGDCWVVAALAAIASQPSLLSRTIPTGQSFVVEWYAGIFAFRWFWRFGRWE	240
SmCalp1	EVLIDDRLPVRQGRNTLVFEMHSNDPTEFWSALEKAYAKLNGCYAHLSSGGSQSEAMEDLT	260
SmCalp2	EVYIDDRLPVKSGGQP-LFVHSGRSTEFWPTLLEKAYAKLNGSYEALNVGLVGDAMDLLT	299
SmCalp1	GGICLSLELNQKER-----PSDLIDQLKIYAQRCCMLGCSIDSSVM---EQKMDNGLIGS	312
SmCalp2	GGLTESYTLPGAEDHGLQPPADLDDILIKSFDRLSLITARIKTKGVPGPGFVIVGVFVPG	359
SmCalp1	HAYSLTGVPVN----YRGRQWLMRLRNPWGD-SHEWKGAWCDGSPQWREISEQEKNI	367
SmCalp2	QAFGLTDCRKLRLTDASGSRLLRLVRLRLNLPWSVRVDWTGAWSEGSTEWLSLPPQDRLKV	419
SmCalp1	NLSFTADGEFWMSEDFVTCFSRVEVCHLGLLESLEY---NQNFHGKRRRLDEAIFSGQWQR	424
SmCalp2	GLV-KAQEEFWMSEDFIANFDYLDICHLLTEPPPVISKSSSAYHSIHNFPVHLLRGRWLR	478
SmCalp1	NVNAGGCINNRTTYWTSPQFRITVEDPDPDDDNKCSVLIGLMQTDIRKK--VGADFQPI	482
SmCalp2	GVSCGGRPYIRASHWANPQFRLVINSPEDEPDGFATTVIALMQADRRRLRHRAPRLASI	538
SmCalp1	GEMVYNAPDDLNTLLSRAQLLTRSPIAKS-QFINTREVTAQFRVPPGSYVVIPSTFDPNI	541
SmCalp2	GFVLYRLPAGANPPMPRGFFETNHHIASVDFEFDSREVVKRLKLTPGHYLLVPCITYAADQ	598
SmCalp1	EVNFILRVFSQTSI--TEQELDED-----NTNQGLPDDVIEALKLEDTLLDEDQIEQKF	594
SmCalp2	PGEFLRLLLFDNPDRIESTLERVELSGLAATGPEPDPNYELFQ-----PRLRRLF	649
SmCalp1	LAIRDPKTNAINAVKLGELLNSTLQ-DIPNFQGFNKELCRSMVASVDNNLTGHVELNEF	653
SmCalp2	Y-EASGESMAVDAFQLEPIILNCLLRDDHRAPYSMVSTDACRSEVALLDRDGTGRLCESDF	708
	1	2
SmCalp1	MDIWIQAKGWKHIFIKHDVDQSGYFSAYEFREALNDAGYHVSNRLINAIINRYQDPGTDK	713
SmCalp2	RRVWDILRSWSRLFASFDPORTAHVTSLDFRIIVEQAGYTLPHTLFSKLVNRFVNVDW-R	767
	3	4

SmCalp1	I S F E D F M L C M V R L K T A F E T I E A H P K N I E G T S L F S A E D Y L R F S V Y I	758
SmCalp2	L D Y P H F I S A M S L I T K A V A I F K N - - F D H G G R A V L P L E Q F V E I A M T M	810

5

Supplementary figure S1: Alignment of the predicted amino acid sequences of SmCalp1 and SmCalp2 using CLUSTAL. Dashes indicate gaps introduced to maximize matching. Identical amino acids are white on a black background. The catalytic domain (PC1 and PC2), CBSW domain and EF hand domain are indicated with grey (PC1), red (PC2), light blue and green boxes, respectively, corresponding to the diagram in figure 1C. Indicated in red are conserved catalytic residues (C¹⁵⁴, H³¹³ and N³³⁷ in SmCalp1 and C¹⁹⁴, Q³³⁰ and N²⁹⁶ in SmCalp2). The numbers (1 – 5) below the alignment at the carboxyl end indicate the five EF hand motifs.

SmCalp2	-----M QSNPTS NYSM	11
SjCalp2	-----M QSNQLL NDSL	11
ShCalp2	-----M QSNLPL NCSL	11
CsCalp2	MSVSYDPSALS LANLIESPTVPTKSKAMATSRPQVTGLVPGLFESQAALIH SNTKSFY-T	59
EgCalp2	-----M N-----T	3
SmCalp2	ENKLEENLNICGNAFG-----YGHN-SSSQYKLRDKTGYPDP TPQKYVNDMRTARHNTR	63
SjCalp2	ENKLEHLNVCGDDFG-----YSHN-SNSQYRLRDKTGYPDP TPQRYVNDMQTARHNTR	63
ShCalp2	ENKLEENLNLCGNSFG-----YGHN-SSSQYKLRDKTGYPDP TPQKYVNDMKTARHNTR	63
CsCalp2	EKEISNILKTVRDMGEVQKLISIAQNSSGADTPLRTVND FQNRITPTALMNDLEIE-----	114
EgCalp2	NRS L-----KISNSSLNKIGDY PPLRAVSNAN---FGR ISET	37
SmCalp2	AMLFDPERSPLSSKVTENNYCRASPS PVV--NRPSTVFSFVGGPSSSFEKIRQDLLNSGH	121
SjCalp2	TMMFDSNIGSLSPKVAENNYCRSSPS PMVA-NRPSTVFSFVGGPSSSFEKIRQELLHSGH	122
ShCalp2	AMLFDSERGPLSPKATENNYCRASPS PMV--NRPSTVFSFVGGPSSSFEKIRQDLLQSGH	121
CsCalp2	----NRSKSPMHLNLSASNMCRASPS PSMVMSENNANFI PAGGASSTFEKLRTEALRS GH	170
EgCalp2	DDIFRVSADGQTRFLN---DSGRDSSQMIHDVGPST--KTLPI PSESEFEQIRTEHKMLGR	92
SmCalp2	LFCDSAFPADDSSLYYSQRPPCQIVWMRPSEIVAANS GGGSMGITPRKISTPEFIGEGGI	181
SjCalp2	LFCDSAFPADDSSLYYSQRPPCHIVWMRPSEIVAANS GGGSMGITPRRISTPEFIGEGGI	182
ShCalp2	LFCDSAFPADDSSLYYSQRPPCQIVWMRPSEIVAANS GGGSMGITPRKISTPEFIGEGGI	181
CsCalp2	FYS DATFPADDSSLYYSQRPPCHIVWMRPSEIVA AQS GGGLVGIAPRKMSLPEFISEGGA	230
EgCalp2	LFCDSAFPADETS LYYSRRPPCSIVWMRPPEIVS AMCRTDVLGIAPRKIHFP EFIAGGSI	152
SmCalp2	KLGE LRQGELGDCWVVAALAAIASQPSLLSRTIPTGQSFRVEWYAGIFAFRFRWFRGWEE	241
SjCalp2	KLSELRQGEL-DCWVVAALAAIASQPSLLSRTIPTGQSFRVEWYAGIFAFRFRWFRGWEE	241
ShCalp2	KLGE LRQGELGDCWVVAALAAIAGQPSLLSRTIPTGQSFRVEWYAGIFAFRFRWFRGWEE	241
CsCalp2	KLGE LRQGELGDCWVVAALAAISSQPNLLSRTIPV GQSFRPEWYAGIFAFRFRWFRGHWEE	290
EgCalp2	RLGDLRQGELGDCWVVAALASMTVTPRLTMRSI POGQSFR AEWYAGCFCFRFRWQFGAWEE	212
SmCalp2	VYIDDRLPVKSGGQPLFVHSGRSTEFWPTLLEKAYAKLNGSYEALNVGLVGDAMDDLTGG	301
SjCalp2	VYIDDRLPVRS GGQPLFVHSGRLNEFWPTLLEKAYAKLNGSYEALNVGLVGDAMDDLTGG	301
ShCalp2	VYIDDRLPVKSGGQPLFVHSGRLTEFWPTLLEKAYAKLNGSYEALNVGLVGDAMDDLTGG	301
CsCalp2	VIIDDRIPVRP GGQPLFVHSGRMTEFWPALLEKAYAKLNGSYEALNVGLVGDAMDDLTGG	350
EgCalp2	VIIDDRLPVRP GGRPLFIHSSRHTEFWPALLEKAYAKLSGSYEALNVGLIGDAMDDIIGG	272
SmCalp2	LTESYILPGAEDHGLQPPADLDDILIKSFDRRSLITARIKT-----	342
SjCalp2	LTESYILPGAEEQGLQPPSDLDDILIKSFDRRSLITA-----	338
ShCalp2	LTESYILPGAEDHGLQPPSDLDDILIKSFDRRSLITARIKT-----	342
CsCalp2	LTESYILPAAEEQGILPPPALDDILIKSFDRRSLITARIKV-----	391
EgCalp2	LTESYCLAPGEDQGRPPPDLDDILIKAFDRRSLITARIKASASSSLSGISPSSRLFALT	332
SmCalp2	-----KGVPGPGFVIVPGFVPGQAFGLTDCRKLRLTDASGSRLLRVLRLRN LWPSVRVD	396
SjCalp2	-----PPGPGFVIPAGFVPGQAFGLTDCRKLRLTDASGSRLLRVLRLRN LWPSVRVD	390
ShCalp2	-----KGVPGPGFVIVPGFVPGQAFGLTDCRKLRLTDASGSRLLRVLRLRN LWPSVRVD	396
CsCalp2	-----S-IPGPGFVIVPGFVPGQAFGLTDCRKLRLTDATGSRLVRLVRLRN LWPSVRVG	444
EgCalp2	ALHRRTKGSPCSGFVLPQGFVPGQAFGLTDCRKLRLTDVSGSRLVRLVRLRN LWPSARVG	392

SmCalp2	WTGAWSEGSTTEWLSLPPQDRLEKVGLVKAQEEFWMSLEDFIANFDYLDICHLTEPPPVISK	456
SjCalp2	WTGAWSEGSTTEWLSLPPQDRLEKVGLVKAQEEFWMSIEDFVANFDYLDICHLTEPPPVISK	450
ShCalp2	WTGAWSEGSTTEWLSLPPQDRLEKVGLVKAQEEFWMSLEDFIANFDYLDICHLTEPPPVISK	456
CsCalp2	WTGAWSEGSNEWLSLPAQDRLEKVGLVKSDDDEFWMSLEDFIANFDYLDICHLTEPAPPTPS	504
EgCalp2	WVGAWSEGSSEWLSLPPEDRIKVGLVKGEGEFWMSMEDFLANFDYLDICHVLEPPSGDAG	452

SmCalp2	SSSA-----YHSLHNFPSVHLRGRWLRGVSCGGRPYIRASHWANPQFRIV	501
SjCalp2	PSNA-----YHSTYHFPSVHLRGRWLRGVSCGGRPYIRASHWANPQFRIG	495
ShCalp2	SSSA-----YHSLHNFPSVHLRGRWLRGVSCGGRPYIRASHWANPQFRIV	501
CsCalp2	SPTP-----IQTMPNFPAAHLRGRWLRGVSCGGRPYIRTSHWANPQFRIL	549
EgCalp2	GGRLFCGTVATTGNHQAPVGPAMETWTTPRFEGRWVRGVVTAGGRPFVRAASHWANPQFVVS	512

SmCalp2	INSPDPNDPDGEATTVIALMQADRRRLRHRAPRLASIGFVLYRLPAGANPPMPPRGFFETN	561
SjCalp2	INSPDPTDPEGLATTVIALMQADRRRLRHRAPRLASIGFVLYRLPSGANPPMPPRGFFETN	555
ShCalp2	INSPDPNDLDGEATTVIALMQADRRRLRHRAPRLASIGFVLYRLPAGANPPMPPRGFFETN	561
CsCalp2	IGSADPNDDGLAAVVIALMQADRRRLRHRAPRLASIGFVLYRLPAGSHPPMPRAFFESN	609
EgCalp2	LPTPDVGDPEGLTAVVALLQSDVRPLRHRAPRLLSIGFVLYRLPPGASPPMTRHFFETIT	572

SmCalp2	HHIASVDFFFDSREVVKRIKLTTPGHYLLVPCTYAADQPGEFLLRLLFDNPDRICESTLER	621
SjCalp2	HHIASVDFFFDSREVVKRIKLTTPGHYLLVPCTYAADQPGEFLLRLLFDHPDRICEPTLER	615
ShCalp2	HHIASVDFFFDSREVVKRIKLTTPGHYLLVPCTYAADQPGEFLLRLLFDNPDRICESTLER	621
CsCalp2	HHVASVDFFFDSREVVKRIKLTTPGHYLLVPCTYAPDQPGEFLLRILFDQADRSCPALER	669
EgCalp2	SHVASVDYFYDSREVVKRFRLVPGVYLLVPCTYAADQPGEFLLRVLFEQSDRTLELALGP	632

SmCalp2	VELSGLAA--TGPELDPNYELFQPRIRRLRYEASGESMAVDAFQLEPILNCLLRDDHRAPY	680
SjCalp2	VELSGLAA--TGPELDPNYELFQPRIRRLRYEASGESMAVDAFQLEPILNCLLRDDHRAPY	674
ShCalp2	VELSGLAA--TGPELDPNYELFQPRIRRLRYEASGESMAVDAFQLEPILNCLLRDDHRAPY	680
CsCalp2	VELSGLAA--NGPESDSQLELIKPRIRRLRYEASGEFAMVDAFQLEPILNSLLRDDHRSPY	728
EgCalp2	IDAGSISPQALSDDPQFDITLPRIRRLRYEASGDSMAVDAFQLDSILNTLLKEDHRLPY	692

1

SmCalp2	SMVSTDACRSLVALLDRDGTGRLCESDFRRVWDILRSWSRLEFASFDPQRTAHVTSLDFRI	740
SjCalp2	NMVSTDACRSLVALLDRDGTGRLCESDFRRVWDILRSWSRLEFASFDPQRTAHVTSLDFRI	734
ShCalp2	SMVSTDACRSLVALLDRDGTGRLCESDFRRVWDILRSWSRLEFASFDPQRTAHVTSLDFRI	740
CsCalp2	TVVTTDACRALVALLDRDGTGRLSESDFHRVWDILRCWSRLEFAAFDPQRTGHVTSLDFRI	788
EgCalp2	ANVSTDACRALIAMRNDRYTGRLVESEFQPTWSSLRCWSRMEFAAFDPQRTGHITCLDFRI	752

2

3


SmCalp2	IVEQAGYTLPHITLFSKLVNRFVNVDRWLDYPHFISAMSLITKAVAIKKNFDHGGRAV-LP	799
SjCalp2	IVEQAGYTLPHITLFSKLVHRFVNVDRWLDYPHFISAMSLITKAVAIKKNFDHGGRAV-LP	793
ShCalp2	IVEQAGYTLPHITLFSKLVNRFVNVDRWLDYPHFISAMSLITKAVAIKKNFDHGGRAV-LP	799
CsCalp2	IVEQAGYTLPHSILSRMVHRFVDVDRWLDYSKFINAMALITKTIKAIKKNYDHHGGRAV-LS	847
EgCalp2	LIEQVGLYLPHITLARIVHREADAERWISYGTFIQIMALLTRAISTFNAESGDGLTLIIH	812

4

5

SmCalp2	LEQFVEIAMTM	810
SjCalp2	LEQFVEIALTM	804
ShCalp2	LEQFVEIAMTM	810
CsCalp2	LEQ-----	850
EgCalp2	LEEYLEALTII	823

Supplementary figure S2: Alignment of the predicted amino acid sequences of the platyhelminth Calp2 clade 2 proteins using CLUSTAL. Dashes indicate gaps introduced to maximize alignment. Amino acids identical in all five sequences are depicted in white with a black background, amino acids found in 4/5 have a grey background and in 3/5 have a light grey background. The catalytic domain (PC1 and PC2), CBSW domain and EF hand domain are indicated with grey (PC1), red (PC2), blue and green boxes, respectively. Red amino acids indicate conserved catalytic residues. The numbers (1 – 5) below the alignment at the carboxyl end indicate the five EF hand motifs. SmCalp2, *S. mansoni* Calp2 (SmCalp2; MF590064); SjCalp2, *S. japonicum* Calp2 (SjCalp2, MF590065); ShCalp2, *S. haematobium* Calp2 (ShCalp2, XP_012791984) CsCalp2, *Clonorchis sinensis* Calp2 (Cs2, GAA29557.2); EgCalp2, *Echinococcus granulosus* Calp2 (Eg2, CDS20315.1).



Supplementary figure S3: The entire blot from figure 6C - western blot analysis of extracts of adult worms exposed to biotinylated E64c (lanes 1), E64c (lanes 2) or untreated control (lanes 3) worms. The blot was probed with streptavidin-HRP, (left panel) to detect biotinylated proteins or with anti-SmCalp1 antibody (center) to detect SmCalp1 or with anti-SmCalp2 antibody (right panel) to detect SmCalp2. Blots were then probed with HRP-labeled secondary anti-antibody. Lanes 1 contain extracts of biotinylated E64c-treated worms, lanes 2 contain extracts of E64c-treated worms, lanes 3 contain extracts of untreated, control worms, The arrowhead indicates the position of migration of SmCalp1 and the arrow indicates the position of migration of SmCalp2. A non-specific streptavidin binding protein is detected at the top of all lanes in the “Streptavidin” panel (left). Some of the additional lower molecular weight, biotinylated moieties seen in “Streptavidin” lane 1 (left) may represent biotinylated SmCalp2 fragments, also detected by the anti-SmCalp2 antibody in “SmCalp2” lanes 1, 2 and 3 (right panel).